What You Should Know:
– Medable Inc., a leader in modern clinical trial technology, has announced a groundbreaking partnership with Masimo (NASDAQ: MASI) to integrate medical-grade wearable devices into clinical research. This collaboration aims to streamline patient participation and enhance data collection for clinical trials.
– By offering a patient-centric approach and fostering richer data collection, this collaboration holds promise for faster drug development, improved patient experiences, and ultimately, advancements in healthcare.
Easing the Burden for Patients
Masimo’s MightySat® Rx pulse oximeter, a trusted medical device used by clinicians globally, is now being incorporated into Medable’s platform. This eliminates the need for frequent, often burdensome, trips to trial sites for routine testing, particularly beneficial for patients with serious illnesses like lung and breast cancer. Over 3,000 patients across eight major oncology trials in 25 countries are already benefiting from this technology.
A Multifaceted Approach to Data Collection
The partnership goes beyond wearables. Medable’s eCOA+ solution allows for subjective data capture through human interaction. When combined with Masimo’s objective sensor data, this creates a richer and more comprehensive dataset for researchers. Medable specifically chose Masimo for its Signal Extraction Technology®, known for delivering accurate readings even in challenging conditions.
Wearables Gaining Traction in Clinical Trials
The use of wearables in clinical trials is on the rise. Currently, 20% of trials utilizing Medable’s platform incorporate wearables, with 35% of those focused on oncology research. This trend highlights the growing recognition of wearables’ potential to improve patient experience and data collection.
Financial Advantages of Decentralized Trials
Research from the Tufts Center for the Study of Drug Development further strengthens the case for decentralized trials. Their findings suggest that decentralized trials can yield a net financial benefit of 5 to 13 times for Phase II and III trials, translating to a potential ROI of $10 million and $39 million respectively, with an average investment of $500,000 and $1.5 million for Phase II and III trials, respectively.
“Medable has always been a leader in digital and decentralized clinical trials, so we are excited to work with a forward-thinking organization with the ambition and ability to transform research,” said Dr. Daniel Cantillon, Chief Medical Officer at Masimo. “Clinical trials require top-in-class accuracy and data quality both on-site and off-site from clinical offices. Medable is solving this problem through its advocacy and by empowering more patients to participate in research. And, Medable’s flexible platform enables scalability and data aggregation for a holistic approach.”
